title: Rheumatoid arthritis: from palliation to remission in two decades.
abstract: The last 20 years have seen a transformation in the landscape of rheumatoid arthritis, which has changed from being a life limiting condition to a chronic but often remitting illness. The importance of early disease control, the better use of existing therapies, and the development of new therapies have all been key to this success. The future of therapy now lies in the identification of stratifying biomarkers, to allow more rational delivery of treatment. The ultimate goal remains the reintroduction of immune tolerance to potentially achieve a 'cure.'
authors.affiliation: Musculoskeletal Research Group, Newcastle University, Newcastle-upon-Tyne, UK.
authors.forename: Philip M
authors.initials: PM
authors.lastname: Brown
authors.affiliation: National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle Hospitals NHS Trust and Newcastle University, Newcastle-upon-Tyne, UK john.isaacs@ncl.ac.uk.
authors.forename: John D
authors.initials: JD
authors.lastname: Isaacs
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000276:immunology / Q000503:physiopathology / Q000628:therapy; D015415:Biomarkers / Q000032:analysis; D006801:Humans; D010166:Palliative Care
chemical_list: D018501:Antirheumatic Agents; D015415:Biomarkers
keywords: Rheumatoid arthritis; biologics; biomarkers; immune tolerance; stratified medicine